"Effectiveness and tolerability of intravenous fosfomycin in treating complicated urinary tract infections caused by Escherichia coli: A prospective cohort study from the FOSFO-MIC Project".
Abstract
OBJECTIVES
The FOSFO-MIC study assessed the clinical and microbiological effectiveness, and safety of intravenous fosfomycin in treating complicated urinary tract infections (cUTIs) caused by Escherichia coli, in comparison with other intravenous antimicrobials.
METHODS
A prospective, multinational matched-cohorts study involving adults with community-acquired cUTIs and receiving targeted therapy with intravenous fosfomycin or other first-line drugs (beta-lactams or fluoroquinolones) was conducted from November 2019 to May 2023 in 10 centres from Spain, Italy, and Türkiye. Matching criteria included healthcare-relation, Charlson and Pitt scores. Endpoints were clinical and microbiological cure, mortality, recurrence, and adverse effects. Analyses used conditional logistic regression and DOOR.
RESULTS
Overall, 155 matched pairs were included. Clinical and microbiological cure rates were 65.2% (101/155; 95% CI: 57.4-72.2) and to 63.2% (98/155; 95% CI:55.4-70.4) with fosfomycin and comparators, respectively (aOR: 1.09; 95% CI:0.68-1.73; p=0.73). Mortality rates were 1.9% (3/155; 95% CI:0.7-5.5) and 5.8% (9/155; 95% CI:3.1-10.7), respectively (p=0.11). Recurrence rates were 14.2% (22/155; 95% CI: 9.6-20.6) in the fosfomycin group versus 10.3% (16/155; 95% CI: 6.1-16.1) (p=0.39). Severe adverse effects occurred in 1.9% (3/155; 95% CI: 0.7-5.5) of patients treated with fosfomycin versus 0.6% (1/155; 95% CI: 0.0-3.3) in the control group (p=0.62). Non-severe adverse effects were…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence.
Read the paper
Related studies
- Association of lower urinary tract symptoms and OAB severity with quality of life and mental health in China, Taiwan and South Korea: results from a cross-sectional, population-based study
- Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter, Randomized, Parallel-Controlled Clinical Trial in China
- The Role of the NLR and PLR in Urinary Tract Infection
- Threat of Antimicrobial Resistance among Pilgrims with Infectious Diseases during Hajj: Lessons Learnt from COVID-19 Pandemic
- Leclercia adecarboxylata urinary tract infection in a patient with bladder cancer and recurrent hematuria
- A Case Series of Staphylococcus lugdunensis Infection in Cancer Patients at an Academic Cancer Institute in the United States
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.